Premium
Actobiotics™ as a Novel Method for Cytokine Delivery
Author(s) -
Steidler Lothar,
Rottiers Pieter,
Coulie Bernard
Publication year - 2009
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2009.05067.x
Subject(s) - cytokine , chemistry , medicine , immunology
Interleukin‐10 (IL‐10) is central in immune downregulation, but so far its use in inflammatory diseases remains cumbersome. For treatment of inflammatory bowel disease, adequate amounts of IL‐10 must reach the intestinal lining. Systemic injection of a pharmacologically active doses of recombinant human (rh) IL‐10 results in very low mucosal levels of protein and severe toxicity and side effects. In animal models, topical and active delivery of IL‐10 by ingestion of recombinant Lactococcus lactis ( L. lactis ) was shown to be a valuable alternative. Starting thereof we have developed a novel pharmaceutical platform. Our expertise and TopAct™ (topical and active) delivery technology allows use of recombinant L. lactis – ActoBiotics™– in clinical practice. Here we discuss the development of recombinant L. lactis for intestinal delivery of rhIL‐10 in humans.